

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY COSTA RICA	2. DATE OF BIRTH			2a. AGE 54 Years	3. SEX Female	3a. WEIGHT 76.70 kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER	
		Day	Month	Year			Day	Month	Year			
										PRIVACY	MAY	2025

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
terrible diarrhea [Diarrhoea]
Pain [Pain]
Candida infection [Candida infection]

Case Description: ***This is an auto generated narrative***

Study ID: 828652-My Healthy Journey

Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining
 (Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1) 3 mg, qd	16. ROUTE(S) OF ADMINISTRATION #1) Subcutaneous	
17. INDICATION(S) FOR USE #1) Obesity (Obesity)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) NOV-2024 / Unknown	19. THERAPY DURATION #1) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) IRBESARTAN (IRBESARTAN) ; Ongoing #2) HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) Tablet ; Ongoing #3) LOVASTATIN (LOVASTATIN) ; Ongoing #4) THYROXINE (LEVOTHYROXINE SODIUM) Tablet ; Ongoing #5) GABAPENTIN (GABAPENTIN) Tablet ; Ongoing #6) VENLAFAXINE (VENLAFAXINE) Tablet ; Ongoing (Continued on Additional Information Page)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Current Condition	Obesity (Obesity)
	Duration not reported.	
Unknown to Ongoing	Current Condition	Glaucoma (Glaucoma)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888		26. REMARKS Medically Confirmed: No
	24b. MFR CONTROL NO. 1460017	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 12-JUN-2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 09-JUL-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

09-Jul-2025 08:49

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

strategies (only for patients under Liraglutide 3.0 mg).

Patient's height: 157 cm.

Patient's weight: 76.7 kg.

Patient's BMI: 31.116881.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "terrible diarrhea(Diarrhea)" beginning on MAY-2025 , "Pain(Pain)" beginning on MAY-2025 , "Candida infection(Candida infection)" beginning on MAY-2025 and concerned a 54 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from NOV-2024 for "Obesity",

Dosage Regimens:

Saxenda: ??-NOV-2024 to Not Reported;

Current Condition: Obesity, Glaucoma in prevention, Hypertension, Insulin resistance, Menopause, Depression, knee pain, cramps, High cholesterol

Procedure: Arthroscopy.

Concomitant medications included - IRBESARTAN, HYDROCHLOROTHIAZIDE, LOVASTATIN, THYROXINE(LEVOTHYROXINE SODIUM), GABAPENTIN, VENLAFAXINE, ACETYLSALICYLIC ACID.

Batch Numbers:

Saxenda: UNK;

Action taken to Saxenda was reported as Drug discontinued temporarily.

The outcome for the event "terrible diarrhea(Diarrhea)" was Recovering/resolving.

The outcome for the event "Pain(Pain)" was Recovering/resolving.

The outcome for the event "Candida infection(Candida infection)" was Recovering/resolving.

Reporter's causality (Saxenda) -

terrible diarrhea(Diarrhea) : Unknown

Pain(Pain) : Unlikely

Candida infection(Candida infection) : Unlikely

Company's causality (Saxenda) -

terrible diarrhea(Diarrhea) : Possible

Pain(Pain) : Unlikely

Candida infection(Candida infection) : Unlikely

Reporter Comment: Patient was given NSAIDs (allergic to Non-Steroidal Anti-Inflammatory Drugs) for events pain and a Candida infection. (Non specified and non codable)

Saxenda was paused until the date: June 10, 2025.

Treatment: Ovals for Candida and Enterogermina for diarrhea. (Non codable and non specified)

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION continued

#7) ACETYLSALICYLIC ACID (ACETYLSALICYLIC ACID) ; Unknown

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Current Condition	Hypertension (Hypertension);
Unknown to Ongoing	Current Condition	Insulin resistance (Insulin resistance);
Unknown to Ongoing	Current Condition	Menopause (Menopause);

ADDITIONAL INFORMATION

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Current Condition	Depression (Depression);
Unknown to Ongoing	Current Condition	Knee pain (Arthralgia);
Unknown to Ongoing	Current Condition	Cramps (Muscle spasms);
Unknown to Ongoing	Current Condition	High cholesterol (Blood cholesterol increased);
Unknown to Ongoing	Procedure	Arthroscopic surgery (Arthroscopic surgery);